Small cell carcinoma of the bladder splits into two phenotypes with different drug targets

Design

Retrospective multi-institutional immunohistochemistry cohort with FISH for NECTIN4

Population

88 small cell carcinomas of the bladder, 79 with full immunohistochemical characterisation

Primary outcome

Transcription-factor-defined subgroup and therapeutic biomarker expression

Effect

ASCL1 41.8%, NEUROD1 25.3%, POU2F3 20.3%, YAP1 6.3%; NECTIN4 amplified in 21.9% (16/73)

Small cell carcinoma of the bladder is rare enough that it is usually managed by analogy with small cell lung carcinoma. This cohort tested whether the transcription-factor taxonomy developed for the lung also organises the bladder tumours.

Eighty-eight cases were assembled across institutions, 79 characterised by immunohistochemistry for ASCL1, NEUROD1, POU2F3, YAP1 and HNF4α alongside conventional neuroendocrine markers and therapeutic targets. Six subgroups emerged: ASCL1-driven in 41.8%, NEUROD1-driven in 25.3%, POU2F3-driven in 20.3%, YAP1-driven in 6.3%, mixed in 5.1% and fully negative in 1.3%. These collapse usefully into two: high neuroendocrine tumours with diffuse marker expression, and low neuroendocrine tumours with weak or absent expression.

The therapeutic biomarkers separate along the same line. DLL3 and SLFN11 were overexpressed in the high neuroendocrine group. Membranous Nectin-4 was low or absent overall but significantly higher in the low neuroendocrine group, while NECTIN4 amplification occurred in 21.9% — a rate comparable to ordinary urothelial carcinoma, and a reminder that amplification and membranous protein expression are not the same question.

• A four-antibody transcription factor panel is enough to assign the phenotype
• Report the neuroendocrine marker pattern explicitly; it is what separates the two therapeutic groups
• Do not infer Nectin-4 protein expression from NECTIN4 amplification — this series shows them dissociating
• Most other antibody-drug conjugate targets were essentially absent, so a broad panel adds little
• This is a classification and biomarker study; none of these groups yet has a trial behind it

Why it matters

It gives a rare tumour a reproducible sub-classification at a point when antibody-drug conjugates are being chosen on the assumption that bladder means Nectin-4.

Don't overread it

Retrospective, and entirely biomarker expression. No outcome data and no treatment response data are reported, so this predicts target availability, not benefit.

The statistics, in plain English

The subgroup percentages come from 79 stained cases, so the smallest groups — YAP1-driven at 6.3% and fully negative at 1.3% — rest on five and one case respectively and should be treated as observations rather than estimates. The Nectin-4 comparison reached P < 0.001, which is solid, but the clinically relevant fact is that overall membranous expression was low in both groups.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.